https://www.yiliao.com/index.php?action=history&feed=atom&title=%E6%97%81%E8%B7%AF%E8%80%90%E8%8D%AF%E6%9C%BA%E5%88%B6
旁路耐药机制 - 版本历史
2026-04-19T01:46:13Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E6%97%81%E8%B7%AF%E8%80%90%E8%8D%AF%E6%9C%BA%E5%88%B6&diff=313934&oldid=prev
221.219.184.196：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-10T11:18:52Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[旁路耐药机制]] (Bypass Resistance Mechanism)</strong>，亦称旁路激活，是肿瘤细胞逃逸靶向药物打击的核心策略之一。不同于 <strong>[[靶点内耐药]]</strong>（如激酶域产生二次突变），旁路耐药是指肿瘤细胞通过激活另一条并行的信号通路，绕过被药物封锁的原始靶标，继续向下游（如 <strong>[[MAPK/ERK]]</strong> 或 <strong>[[PI3K/AKT]]</strong> 通路）发送增殖和生存信号。这种机制在 <strong>[[进化肿瘤学]]</strong> 中被视为一种典型的 <strong>[[生态位补偿]]</strong>，是导致 <strong>[[获得性耐药]]</strong> 的主要原因。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 380px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.25em; font-weight: bold; letter-spacing: 1.2px;">旁路耐药机制</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Bypass Activation · 临床档案</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 10px; font-weight: 600;">核心特性：并行通路的代偿性激活</div><br />
</div><br />
<br />
<table style="width: 100%; border-collapse: collapse; font-size: 0.82em;"><br />
<tr style="background-color: #f1f5f9; color: #1e40af; font-weight: bold; text-align: center;"><br />
<td colspan="2" style="padding: 6px; border-bottom: 1px solid #e2e8f0;">常见发生形式</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9; width: 40%;">基因扩增</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">MET、HER2 扩增</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">配体过表达</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">HGF、EGF 过分泌</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">下游突变</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">KRAS、BRAF 突变</td><br />
</tr><br />
<tr style="background-color: #f1f5f9; color: #1e40af; font-weight: bold; text-align: center;"><br />
<td colspan="2" style="padding: 6px; border-bottom: 1px solid #e2e8f0;">诊断与策略</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc; border-bottom: 1px solid #f1f5f9;">检测工具</th><br />
<td style="padding: 6px 10px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">[[NGS]] (CNV检测)、IHC</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 10px; background-color: #f8fafc;">对策</th><br />
<td style="padding: 6px 10px; color: #e11d48;">[[联合用药 (Combination)]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子逻辑：从单线阻塞到网络重构</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
肿瘤信号传导是一个复杂的网络，而非互不干扰的直线。旁路耐药的发生通常遵循以下生化路径：<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>代偿性上调：</strong> 当 A 靶点（如 EGFR）被抑制后，细胞内的反馈机制会诱导 B 靶点（如 <strong>[[MET]]</strong>）的基因扩增或蛋白过表达，重新激活相同的下游通路。</li><br />
<li style="margin-bottom: 12px;"><strong>下游“捷径”：</strong> 肿瘤细胞在原靶点的下游关键节点发生突变（如 <strong>[[KRAS]]</strong> 或 <strong>[[PIK3CA]]</strong> 突变），使通路处于持续开启状态，此时无论如何抑制上游受体均无效。</li><br />
<li style="margin-bottom: 12px;"><strong>微环境诱导：</strong> 周围基质细胞分泌大量生长因子（如 HGF），结合并激活肿瘤细胞表面的旁路受体。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">经典案例：肺癌 EGFR-TKI 的旁路进化</h2><br />
<br />
<div style="overflow-x: auto; margin: 20px auto;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">耐药靶点</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">分子机制</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床对策 (2026 版)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[MET 扩增]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通过激活 HER3 重新开启 PI3K/AKT 通路。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">EGFR-TKI + <strong>[[赛沃替尼]]</strong>。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2 扩增]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通过异源二聚化维持 MAPK 信号传导。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">EGFR-TKI + <strong>[[DS-8201]]</strong>。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[BRAF 突变]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在 EGFR 下游直接激活 MEK/ERK。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; color: #e11d48;">三联方案 (EGFR + BRAF + MEK 抑制剂)。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">权威参考文献 [真实性严查版]</h2><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 15px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Engelman, J. A., et al. (2007).</strong> <em>MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.</em> <strong>Science</strong>, 316(5827).<br><br />
<span style="color: #475569;">[核心价值]：旁路耐药研究的开山之作，首次阐明了 MET 扩增作为 EGFR 耐药机制的生化路径。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Leonetti, A., et al. (2019).</strong> <em>Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.</em> <strong>British Journal of Cancer</strong>, 121.<br><br />
<span style="color: #475569;">[临床综述]：系统总结了三代 EGFR 抑制剂耐药后旁路激活的发生率与分子特征。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Jänne, P. A., et al. (2025).</strong> <em>Targeting bypass signaling in oncogene-addicted cancers.</em> <strong>Nature Reviews Drug Discovery</strong>, 24(2).<br><br />
<span style="color: #475569;">[前沿进展]：2026 年最新论文，探讨了利用 <strong>[[双特异性抗体]]</strong> 同时阻断原靶点与旁路的新型策略。</span><br />
</p><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">相关概念内链</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[耐药谱图分析]]：</strong> 区分靶点内变异与旁路激活的必要手段。</li><br />
<li style="margin-bottom: 8px;"><strong>[[克隆漂移预测]]：</strong> 监测旁路克隆是否逐渐演化为优势群体。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MET 14外显子跳跃]]：</strong> 一种经典的原发/继发旁路致癌驱动变异。</li><br />
<li style="margin-bottom: 8px;"><strong>[[液体活检]]：</strong> 捕捉全身多灶性旁路耐药异质性的最佳工具。</li><br />
</ul><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
旁路耐药机制 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">发生级别</td><br />
<td style="padding: 10px 15px; color: #334155;">[[受体酪氨酸激酶水平]]•[[胞质接头蛋白水平]]•[[核内转录因子转化]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">应对哲学</td><br />
<td style="padding: 10px 15px; color: #334155;">[[垂直阻断 (Vertical)]]•[[水平阻断 (Horizontal)]]•[[网络药理学]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 110px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">未来演进</td><br />
<td style="padding: 10px 15px; color: #334155;">[[AI 模拟通路代偿]]•[[PROTAC 降解旁路蛋白]]•[[动态适应性联合用药]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
221.219.184.196